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Objectives. We sought to evaluate the impact of angiographi-
cally visible thrombus on short- and long-term clinical out-
comes after percutaneous transluminal coronary angioplasty
(PTCA).
Background. Intracoronary thrombus is frequently seen on
angiography in patients with acute ischemic coronary syndromes
or complex lesion morphology, or both, and is often considered to
predict a higher rate of complications in patients undergoing
PTCA.
Methods. Prospectively collected data from 2,099 patients un-
dergoing high risk PTCA in the Evaluation of IIb/IIIa Platelet
Receptor Antagonist 7E3 in Preventing Ischemic Complications
(EPIC) trial were analyzed. In addition to aspirin and heparin,
patients were randomized to receive either abciximab bolus and
infusion, abciximab bolus alone or placebo. Based on an angio-
graphic core laboratory interpretation, patients were classified
into three groups: thrombus absent, thrombus possible or throm-
bus present. The primary end point at 30 days was the composite
of death, myocardial infarction or urgent revascularization. The
6-month end point was the composite of death, myocardial
infarction or any revascularization.
Results. Although abrupt closure was most common in patients
with thrombus present compared with thrombus absent or possi-
ble (13%, 10.0% and 7.4%, respectively), neither the 30-day nor the
6-month clinical end points were different among the three groups
(9%, 11% and 11.7%, respectively, and 30%, 34% and 31%,
respectively). Most notably, the benefit of treatment with abcix-
imab was present in all three thrombus groups, and the magni-
tude of benefit was not different among the thrombus groups.
Conclusions. In high risk patients undergoing percutaneous
coronary revascularization, features of thrombus on the prepro-
cedure angiogram do not indicate an augmented risk of adverse
clinical outcomes. Abciximab therapy reduces the rate of adverse
outcomes regardless of the presence of thrombus and should
therefore not necessarily be reserved for patients whose angio-
grams have features of intraluminal thrombus.
(J Am Coll Cardiol 1998;31:31–6)
©1998 by the American College of Cardiology
Intracoronary thrombus is frequently seen in patients with the
acute coronary syndromes of myocardial infarction (MI) and
unstable angina (1–4), as well as in coronary stenosis with
complex lesion morphology (5), and has been implicated in the
genesis of restenosis (6–8), abrupt closure (9,10), distal em-
bolization, “no-reflow” and periprocedural MI (11,12). Al-
though generally regarded as an unfavorable feature in pa-
tients undergoing percutaneous transluminal coronary
angioplasty (PTCA), intracoronary thrombus has had a vari-
able impact on clinical outcomes (10,13–20) and has not been
studied in the era of aspirin, activated clotting time (ACT)-
directed heparin therapy and glycoprotein IIb/IIIa inhibitors.
A frequent practice is to treat such patients with 3 or more
days of intravenous heparin therapy (14). However, the utility
of this approach has not been validated prospectively. As more
patients with complex lesion morphology and acute coronary
syndromes are treated with PTCA, and as the impetus to
shorten hospital stays increases, it becomes increasingly impor-
tant to assess the clinical importance of intracoronary throm-
bus.
Abciximab, a monoclonal antibody directed at the platelet
glycoprotein IIb/IIIa receptor complex, markedly inhibits
platelet aggregation both ex vivo and in vivo (21), prevents
arterial occlusion in a variety of experimental models (22–24)
and reduces ischemic complications in patients undergoing
high risk PTCA (25,26). Because of its antithrombotic proper-
ties, abciximab might be expected to be of greater benefit in
patients with preexisting thrombosis compared with other high
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risk patients. The purpose of this study, therefore, was twofold:
first, to evaluate the impact of angiographically evident intra-
coronary thrombus immediately before angioplasty on the
immediate and late clinical outcomes after the procedure; and
second, to determine whether patients with angiographically
visible thrombus benefited more from glycoprotein IIb/IIIa
inhibition with abciximab than did other high risk patients.
Methods
Study group. Prospective data were collected from the
patients enrolled in the Evaluation of IIb/IIIa Platelet Recep-
tor Antagonist 7E3 in Preventing Ischemic Complications
(EPIC) trial. Patients undergoing high risk PTCA or direc-
tional atherectomy were enrolled in this multicenter, placebo-
controlled, double-blind trial of the platelet glycoprotein IIb/
IIIa receptor antagonist, abciximab (ReoPro). The details of
inclusion, exclusion and trial design have been published
previously (25,27). Briefly, the inclusion criteria included 1)
acute MI with primary or rescue angioplasty within 12 h of
onset; 2) early postinfarction angina or unstable angina with at
least two episodes of rest chest pain accompanied by electro-
cardiographic changes; or 3) two or more type B2 lesion
characteristics or one type C lesion characteristic according to
the American College of Cardiology/American Heart Associ-
ation (ACC/AHA) classification. A total of 2,099 patients were
enrolled. Data on 44 patients were lost or not analyzable;
angiograms from 2,055 patients were therefore analyzed.
Study protocol. All patients received oral aspirin, 325 mg/
day. Heparin was given intravenously on initiating the proce-
dure with a recommendation to maintain an ACT .300 s.
Patients were randomly assigned to one of the three treatment
groups; abciximab bolus and infusion, abciximab bolus alone or
placebo. Study medication was started 10 min before the
procedure. Angiograms were obtained in orthogonal views
before and after the procedure. Case report forms documented
all clinical events.
End points. The primary end point at 30 days was the
composite of death, MI or urgent revascularization for isch-
emia. Six-month follow-up included the composite end point of
death, MI or revascularization. In addition, the following
angiographic end points were analyzed: procedural failure
(defined as .50% stenosis at the end of the procedure), abrupt
closure, major dissection (spiral dissection or dissection length
.10 mm) and total occlusion (defined as 100% stenosis at the
end of the procedure).
Data analysis. All baseline angiograms were reviewed by
two experienced observers at an angiographic core laboratory.
The observers had no knowledge of the treatment group or
clinical outcome. Angiograms immediately before PTCA were
used to evaluate thrombus. Caliper measurements were made
of the reference diameter, minimal lumen diameter (MLD)
and postprocedural MLD, and percent stenosis was calculated.
Thrombus was defined as a filling defect or haziness visible on
two or more orthogonal views. If the filling defect was seen in
one view only, it was called possible thrombus. Based on the
angiographic interpretation, patients were classified into
thrombus absent, thrombus possible or thrombus present
groups.
Statistical methods. The primary end point was analyzed
by the time to the first occurrence of any of the components of
the composite end point within 30 days. All analyses were by
intention to treat; cumulative event rates were estimated using
Kaplan-Meier survival curves. Angiographic outcomes were
assessed as binary end points. A likelihood ratio chi-square test
was used to compare all three groups at the same time. If the
resulting p value was significant, pairwise comparisons were
carried out. Categoric variables are presented as percentages,
and continuous variables are presented as median values (25th
and 75th percentiles).
Results
Patients in the three groups did not differ in their baseline
demographic characteristics or distribution of lesions across
the vessels (Table 1). As expected, there was a larger propor-
tion of patients with acute or recent MI in the thrombus
possible and thrombus present groups. There were also more
patients with total occlusions at baseline in the thrombus
possible and thrombus present groups. Patients with unstable
angina were equally distributed across the groups. Lesion
characteristics and the use of heparin before PTCA are given
in Tables 2 and 3, respectively. Patients with thrombus present
were more likely to have irregular or ulcerated lesions, but
there were no differences between the groups in the frequency
of other adverse lesion characteristics or the use of heparin
during the 24 h before the procedure. Angiographic outcomes
are shown in Table 4. Angiographic failure (.50% residual
stenosis) occurred in 17% of patients with thrombus absent
compared with 22% and 20% in the thrombus possible and
present groups, respectively (p 5 0.04). The abrupt closure
rate was 13% in the thrombus present group and 11% in the
thrombus possible group. These rates were higher than the
abrupt closure rate of 7.6% in the thrombus absent group (p 5
0.002). Major dissections were seen in 14% of the thrombus
absent group compared with 20% in the thrombus possible
group and 28% in the thrombus present group (p , 0.001).
Total occlusion, at the end of procedure, was present in ,1%
in the thrombus absent group, 3.6% in the thrombus possible
group and 2.5% in the thrombus present group (p , 0.001).
Abbreviations and Acronyms
ACC/AHA 5 American College of Cardiology/American Heart
Association
ACT 5 activated clotting time
EPIC 5 Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3
in Preventing Ischemic Complications (trial)
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary angioplasty
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In contrast to the differences in angiographic outcomes,
there were no significant differences between the three groups
in clinical outcome at short-term (30 days) or long-term (6
months) follow-up (Table 5). The overall composite end point
at 30 days occurred in 9%, 11% and 11.7% of patients with
thrombus absent, possible and present, respectively (p 5 NS)
(Fig. 1). At 6 months, the composite end point occurred in
30%, 34% and 31% of patients with thrombus absent, possible
and present, respectively (p 5 NS). Breakdown of the com-
posite end point into death, death or MI and revascularization
categories also failed to show any significant differences in any
component at either 30 days or 6 months (Table 6). Further
analysis, taking into account the assigned treatment group,
showed no significant differences in outcome within each
treatment group regardless of the thrombus category (Table
5). Treatment with abciximab was actually most effective in
patients without thrombus (Fig. 2 and 3).
Discussion
The current study is the first large, prospective study to
assess specifically the immediate and late clinical outcomes of
PTCA in a cohort of patients undergoing high risk angioplasty
with or without angiographically evident intracoronary throm-
bus. The composite end points were designed to evaluate the
overall morbidity from periangioplasty complications and long-
term outcome. Although intracoronary thrombus was fre-
quently present, it did not confer an increased risk of subse-
quent ischemic events, and the benefit of glycoprotein IIb/IIIa
inhibition with abciximab was unaffected by the presence or
absence of thrombus. The overall incidence of intracoronary
thrombus of 34.5% in the patient group reflects the high risk
patient group, which included, by design, a large proportion of
patients with unstable angina or recent MI.
Comparison with previous studies. The current results
confirm findings of previous studies that showed a higher
incidence of adverse angiographic events, specifically proce-
dural failure and periprocedural abrupt closure in patients with
thrombus evident at the time of angioplasty (11,15–20). Sugrue
et al. (17) reported abrupt closure in 24% of patients under-
going angioplasty with intracoronary thrombus. Mabin et al.
(19) reported abrupt closure in 73% of patients with thrombus
compared with 8% in those without thrombus. Although acute
occlusion was more common in the thrombus possible and
present groups, the magnitude of the difference in the present
study is smaller than that previously reported and failed to
Table 1. Baseline Demographic Features
Baseline Characteristics
Thrombus
Absent
(n 5 849)
Thrombus
Possible
(n 5 496)
Thrombus
Present
(n 5 710)
Age (yr) 62 (53, 69) 61 (52, 62) 61 (52, 67)
Men 576 (68%) 360 (73%) 545 (77%)
Heparin therapy in preceding 24 h 394 (55%) 236 (56%) 352 (58%)
Emergency procedure 21 (2.5%) 35 (7.2%)* 56 (8.0%)*
Unstable angina 190 (22%) 111 (22%) 184 (26%)
Acute MI 3 (0.2%) 25 (4.1%)* 37 (4.9%)*
Recent MI (,7 days) 212 (25%) 123 (26%) 248 (35%)
Recent MI (8 to 30 days) 88 (10%) 76 (15%) 111 (16%)
Hypertension 460 (55%) 274 (55%) 378 (54%)
Current smokers 268 (32%) 164 (33%) 248 (35%)
Hypercholesterolemia 476 (60%) 250 (54%) 374 (56%)
Diabetes 212 (25%) 128 (26%) 161 (23%)
Previous PTCA 207 (25%) 97 (20%) 146 (21%)
Previous CABG 118 (14%) 54 (11%) 131 (18%)
Proximal vessel disease 307 (36%) 186 (38%) 242 (34%)
Multivessel disease 365 (40%) 236 (48%) 344 (49%)
.1 lesion dilated 237 (28%) 189 (39%) 229 (33%)
Total occlusion 1 (0.1%) 129 (21%)* 100 (13%)*
High risk anatomy 330 (39%) 202 (41%) 335 (47%)
*p , 0.05 versus thrombus absent group. Data presented are median (25th,
75th percentiles) or number (%) of patients. CABG 5 coronary artery bypass
graft surgery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty.
Table 2. Lesion Morphology
Lesion Characteristic
Thrombus
Absent
Thrombus
Possible
Thrombus
Present
AHA/ACC lesion type
A or B1 38% 35% , 1%
B2 51% 52% 84%
C 11% 13% 15%
Angulation .45° 25% 29% 28%
Calcification 42% 44% 41%
Preprocedural stenosis 70% (62%, 76%) 78% (69%, 99%) 76% (66%, 85%)
Eccentric 44% 51% 55%
Irregular or ulcerated 20% 34% 99%
Length .20 mm 3.4% 2.7% 4.8%
Ostial location 17% 20% 16%
Data presented are median (25th, 75th percentiles) or percent of patients.
AHA/ACC 5 American Heart Association/American College of Cardiology.
Table 3. Preprocedural Heparin Administration
Preprocedural
Heparin Used
Thrombus
Absent
Thrombus
Possible
Thrombus
Present
No heparin before PTCA 56% 55% 53%
,24 h before PTCA 13% 15% 16%
.24 h before PTCA 30% 30% 31%
PTCA 5 percutaneous transluminal coronary angioplasty. Data presented
are percent of patients.
Table 4. Angiographic Outcomes
Angiographic Outcome
Thrombus
Absent
Thrombus
Possible
Thrombus
Present
.50% residual stenosis 140 (17%) 106 (22%)* 136 (20%)
Abrupt closure 63 (7.6%) 50 (11%)† 88 (13%)†
Major dissection 113 (14%) 92 (20%)‡ 189 (28%)‡
Total occlusion 4 (, 1%) 17 (3.6%)‡ 17 (2.5%)‡
*p , 0.04 versus thrombus absent group. †p , 0.07 versus thrombus present
group. ‡p , 0.005 versus thrombus absent group. Data presented are number
(%) of patients.
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translate into a significant difference in adverse clinical out-
comes at 30 days or 6 months. This lack of adverse clinical
outcome may reflect the relatively small differences in the
abrupt closure rates between the groups with and without
thrombus, as well as the routine use of preprocedural aspirin,
ACT-guided use of heparin, improved operator experience
and technical advancements leading to improved management
of abrupt closure in recent years. Most of the previous studies
were done 5 to 10 years ago and most were retrospective
analyses of a smaller number of patients. Certainly, the oper-
ator does have knowledge of the presence of thrombus;
operator-dependent adaptation of the procedure may result in
better outcome. Alternatively, operators may have elected not
to perform angioplasty in some patients with intracoronary
thrombus and may have thus selected a lower risk group.
The lack of adverse clinical outcomes in the present study is
in keeping with other studies that failed to link angiographic
presence of intracoronary thrombus conclusively with perian-
gioplasty complications (10,13,14,17). Detre et al. (28) ana-
lyzed the data from the National Heart, Lung and Blood
Institute’s PTCA registry, and although thrombus was associ-
ated with closure in the laboratory, the overall odds ratio for all
closures was not increased. Similarly, Violaris et al. (29)
reported that in 2,950 patients, clinical events (death, MI,
coronary artery bypass graft surgery or repeat PTCA) were not
significantly different between patients with angiographic
thrombus and those without it. Although angiographic resten-
osis (defined as .50% diameter stenosis at follow-up) was
slightly higher in the thrombus group (43.1% vs. 34.4%),
revascularization rates at 6 months were similar between the
two groups (repeat PTCA 17.2% vs. 17%). White et al. (30)
used both angiographic and angioscopic examination and
noted that angiographic thrombi were not associated with a
short-term adverse outcome after PTCA.
The present study also found no increase in the require-
ment for revascularization at 6 months in patients with angio-
graphic thrombus. Although ample experimental data impli-
cate thrombosis as an important factor in the process of
restenosis (6,8,31,32), it is unclear whether a critical amount of
thrombus is required. Angiography is not the most sensitive
Figure 1. Effect of abciximab bolus and infusion on the 30-day
composite end point in the thrombus absent, thrombus possible and
thrombus present groups. Treatment with the bolus plus infusion is
compared with treatment with placebo. Diamonds 5 odds ratios;
horizontal lines 5 95% confidence intervals.
Figure 2. Effect of abciximab bolus and infusion on the 6-month
composite end point in the thrombus absent, thrombus possible and
thrombus present groups. Treatment with the bolus plus infusion is
compared with treatment with placebo. Diamonds 5 odds ratio;
horizontal lines 5 95% confidence intervals.
Table 5. Frequency of Composite End Point
Thrombus
Absent
(n 5 849)
Thrombus
Possible
(n 5 496)
Thrombus
Present
(n 5 710)
30-day end point
Abciximab bolus plus
abciximab infusion
18/289 (6.2%) 15/154 (9.7%) 20/242 (8.3%)
Abciximab bolus 26/280 (9.3%) 19/176 (11%) 32/229 (14%)
Placebo 35/274 (13%) 21/166 (13%) 31/239 (13%)
Total 79/843 (9%)* 55/496 (11%)* 83/708 (11.7%)*
6-mo composite end
point
Abciximab bolus plus
abciximab infusion
67/286 (23%) 51/151 (34%) 63/235 (27%)
Abciximab bolus 87/276 (32%) 61/175 (35%) 70/229 (31%)
Placebo 97/271 (36%) 55/165 (33%) 83/235 (35%)
Total 251/833 (30%)* 167/491 (34%)* 216/695 (31%)*
*p 5 NS. Data presented are number (%) of patients.
Table 6. Elements of Composite End Points at 30 Days and
6 Months*
Thrombus
Absent
(n 5 849)
Thrombus
Possible
(n 5 496)
Thrombus
Present
(n 5 710)
30-day clinical events
Death 1.5% 1.4% 1.5%
Death or MI 6.7% 8.1% 8.2%
Revascularization 5.0% 5.7% 5.0%
6-mo events
Death 3.0% 2.4% 3.1%
Death or MI 10.2% 9.7% 11.5%
Revascularization 25.2% 29.3% 24.7%
*Kaplan-Meier estimates. Data presented are percent of patients. MI 5
myocardial infarction.
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technique to demonstrate intracoronary thrombus; angio-
scopic studies have consistently shown that angiography sys-
tematically underestimates the frequency of intravascular
thrombus (30,33–36). In the high risk group in the current
study, it is likely that a majority of patients had some degree of
thrombus present even when it was not angiographically
evident. This may explain the finding that abciximab therapy
was equally effective in all three groups regardless of the
presence of thrombus.
The patient group in this study was selected because their
coronary targets presented a condition in which thrombosis
was likely to occur. Thus, it is also possible that intracoronary
thrombus is only a marker of such high risk angioplasty and
may have conferred no additional increase in an already
elevated risk level. Interestingly, the number of patients receiv-
ing heparin for ,24 h, 24 to 48 h and .48 h was not
significantly different in the thrombus groups. This finding
minimizes the bias secondary to the use of heparin therapy,
although it does not completely account for the patients who
may have had thrombus present on a previous diagnostic
angiogram, nor does it exclude the possibility that patients with
larger thrombi may have been more likely to receive intrave-
nous heparin therapy.
Study limitations. This study included only high risk pa-
tients, and the results may not be generalized to routine or
otherwise low risk angioplasty. However, thrombus is present
more frequently in the high risk group, and therefore is more
relevant to clinical decision making in this group. The baseline
characteristics in the three groups were not equal in our
patients. The increased number of patients with acute MI and
total occlusions in the thrombus possible or thrombus present
groups, however, would be expected to increase the risk of
adverse outcome and hence would not explain the lack of
impact of thrombus. Another potential limitation of the
present study is the relative insensitivity of angiography for the
presence of intracoronary thrombus. Recent studies with in-
travascular ultrasound and coronary angioscopy have shown
that although angiography frequently does not show mural
thrombus, it continues to be highly specific for larger luminal
thrombi (30,33–36). Angiography remains the most widely
applied technique for coronary imaging and its integration with
the PTCA procedure itself further widens its application. The
statistical power of the study is limited by its sample size. The
power to detect at 25% difference in the frequency of the
30-day composite end point between the thrombus absent and
thrombus possible groups is 0.38, whereas that for the throm-
bus present group is 0.47. However, for the 6-month end point,
the powers are 0.93 and 0.91 for the thrombus absent and
thrombus possible groups, respectively.
Clinical implications. The findings of the current study
suggest that the presence of thrombus on diagnostic coronary
angiography may not adversely affect the clinical outcome of
angioplasty and does not preclude PTCA in the same setting,
if otherwise planned. This approach would help streamline
treatment strategies in patients admitted to the hospital and
may be useful in avoiding the complexities of prolonged
anticoagulation with heparin. A second and critically impor-
tant finding of this analysis is that the benefit of abciximab
therapy in high risk patients is present regardless of the
presence of thrombus. When analyzed by treatment group, the
magnitude of benefit from abciximab treatment was similar
across the groups. The current study would imply that in the
high risk setting, it is more important to recognize this
condition based on clinical and morphologic features rather
than on the actual presence or absence of thrombus. Thus, in
a high risk patient group, consideration for abciximab therapy
should not be reserved only for the patients with angiographi-
cally evident thrombus, but should be based on whether the
clinical or anatomic features imply an elevated level of risk.
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